Modulating retinoid-X-receptor alpha (RXRA) expression sensitizes chronic myeloid leukemia cells to imatinib in vitro and reduces disease burden in vivo. This evidence concerns the gene RXRA and chronic myelogenous leukemia, BCR-ABL1 positive.